Breaking News

Frenova Renal Research Retains SCORR Marketing

May 9, 2014

To develop strategies to support Frenova’s dedication to renal research

Frenova Renal Research has named SCORR Marketing, a marketing communications company focused on drug and device development services, as its agency.
Frenova, formerly the Clinical Studies Group of Fresenius Medical Care North America, is a Phase I-IV drug and device clinical development services company dedicated exclusively to renal research. Frenova’s goal is to provide an intimate understanding of patients affected by kidney disease and to improve the quality of life for people with renal impairment.
“As the industry’s only dedicated renal CRO, Frenova Renal Research is providing something that other CROs can’t," said Cinda Orr, president and chief executive officer of SCORR Marketing. "We helped Frenova unveil its new name and brand identity at the recent Partnerships in Clinical Trials 2014 and are excited to develop strategies that will effectively support Frenova’s mission of improving the lives of those affected by a renal impairment.”

Related Compliance:

  • CROs and Today’s  R&D Landscape

    CROs and Today’s R&D Landscape

    Kristin Brooks, Associate Editor, Contract Pharma||November 9, 2016
    John Lewis of ACRO discusses opportunities, challenges, and the future CRO

  • Choosing Oral Formulations for First-in-man Clinical Trials

    Choosing Oral Formulations for First-in-man Clinical Trials

    Jon Sutch, Senior Manager of Formulation Development, Patheon||October 11, 2016
    Early formulations should be simple, but selecting a simple formulation isn’t as easy as it seems

  • Robust Assay Designs

    Robust Assay Designs

    Tim Wright, Editor, Contract Pharma||October 11, 2016
    Easing the transition from preclinical to clinical research